aDepartment of Psychiatry, Tsao-Tun Psychiatric Center, Department of Health, Executive Yuan, Nantou County bTaiwan Research Association of Health Care, Taichung, Taiwan.
Int Clin Psychopharmacol. 2014 Jul;29(4):235-8. doi: 10.1097/YIC.0000000000000027.
The aim of the present study was to investigate the relationship between 10 psychotropic agents and worsening BMI from overweight to obesity among inpatients with schizophrenia. A total of 138 patients with schizophrenia were recruited in this retrospective study. We included 23 patients with worsening BMI, from overweight (24≤BMI<27 kg/m²) to obesity (BMI≥27 kg/m²), as the case group and 115 patients without a worse BMI as the control group. Data were analyzed to assess the relationships between psychiatric drug use and BMI that worsened from overweight to obesity. Of the 138 patients, 60.9% were men. Their mean age was 47.2±9.7 years, mean age of onset of disease was 32.2±10.4 years, and the mean length of illness 15.0±6.5 years. Valproic acid was found to have a significant impact on the worsening of BMI from overweight to obesity (P<0.05). Age at onset of disease, length of illness, and duration of hospitalization were not associated significantly with worsening of BMI from overweight to obesity. These results call for caution in using valproic acid in schizophrenic inpatients with BMIs indicating overweight or obesity.
本研究旨在探讨 10 种精神药物与住院精神分裂症患者体重指数(BMI)从超重向肥胖恶化的关系。在这项回顾性研究中,共招募了 138 名精神分裂症患者。我们纳入了 23 名 BMI 恶化的患者,从超重(24≤BMI<27kg/m²)到肥胖(BMI≥27kg/m²),作为病例组,115 名 BMI 无恶化的患者作为对照组。分析数据以评估精神药物使用与 BMI 从超重恶化至肥胖的关系。在 138 名患者中,60.9%为男性。他们的平均年龄为 47.2±9.7 岁,平均发病年龄为 32.2±10.4 岁,平均病程为 15.0±6.5 年。丙戊酸被发现对 BMI 从超重向肥胖恶化有显著影响(P<0.05)。发病年龄、病程和住院时间与 BMI 从超重向肥胖恶化无显著相关性。这些结果呼吁在 BMI 提示超重或肥胖的住院精神分裂症患者中使用丙戊酸时要谨慎。